Cite
HARVARD Citation
Bookhart, B. et al. (2014). Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of medical economics. pp. 691-695. [Online].